Join Us

We are 218,761 members in 84 forums discussing 161,211 topics.

Help with Abbreviations

Topic: Anyone in UPenn SURMOUNT/CLEVER study of DTCs?

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Sep 1, 2019 01:44PM

Staceybee wrote:

Is anybody in the SURMOUNT/CLEVER study at UPenn? I am fascinated by the concept of this study and applied to be in it last year, - and would have traveled to participate, but they said that I did not qualify because my cancer was not considered a high enough stage – even though I had 1 of 2 lymph nodes affected (could have been more but my surgeon was against going back and checking more nodes). The study coordinator said I would have qualified if I had a higher oncotype or had chemo.

As I understand it, in the SURMOUNT part of the study, they test a patient's bone marrow from the hip bone for dormant distributed tumor cells (DTCs) and, if found, the patient moves on to taking the anti-malarial drug hydroxychloroquine or everolimus (Affinitor). Then they test again to see if DTCs have been impacted – hopefully lowered or eradicated.

If you are in the study, I would be very interested to hear about how it is going. I showed the study details to my oncologist at a major cancer center and asked if I could get a test for DTCs – she barely looked at it and said they don't do the test at my cancer center. I am super interested in the potential for hydroxychloroquine since it is already used "off-label" for conditions such as rheumatoid arthritis.

Thanks in advance for sharing any experiences!

1/2 SN w 1mm "micromet"; lots of LCIS found in surgery; oncotype=13; age 52 at dx Dx 4/24/2018, ILC, Right, 1cm, Stage IB, Grade 2, 1/2 nodes, ER+/PR+, HER2- (IHC) Surgery 5/22/2018 Lumpectomy: Right Radiation Therapy 7/10/2018 Whole-breast: Breast, Lymph nodes Hormonal Therapy 8/3/2018 Arimidex (anastrozole)
Log in to post a reply

Page 1 of 1 (1 results)

Posts 1 (1 total)

Log in to post a reply

Sep 10, 2019 03:53PM FarAwayToo wrote:

Hi Staceybee, thank you for sharing this info, very interesting!

Here is a link to clinical database.

Here are the inclusion criteria, as far as type and severity of primary cancer:

  • Pathologically-confirmed invasive breast cancer in axillary lymph nodes or tumor with triple negative subtype: negative estrogen receptor (ER), progesterone receptor (PR) and Her2-overexpression by ASCO-CAP guidelines or tumor with a Breast Cancer Recurrence Score of ≥ 25 per the Genomic Health Oncotype DX breast cancer test, or residual disease after neoadjuvant chemotherapy.
So, even though you had cancer in a lymph node they told you your case wasn't "bad enough"? I know a lot of these studies want to concentrate on higher risk patients. Sadly, this means that a lot of time hormone positive/Her2 negative patients are excluded, unless they had extensive involvement or high enough genomic risk.
Dx 8/31/2017, IDC, Right, 2cm, Stage IIA, Grade 2, 0/4 nodes, ER+/PR+, HER2- Dx 9/15/2017, DCIS, Left, 3cm, Stage 0, Grade 1, 0/3 nodes, ER+/PR+, HER2- Chemotherapy 9/29/2017 Adriamycin (doxorubicin), Cytoxan (cyclophosphamide), Taxol (paclitaxel) Hormonal Therapy 2/23/2018 Zoladex (goserelin) Surgery 2/28/2018 Mastectomy: Left, Right Surgery 2/28/2018 Reconstruction (left): Tissue expander placement; Reconstruction (right): Tissue expander placement Hormonal Therapy 4/5/2018 Femara (letrozole) Surgery 8/21/2018 Prophylactic ovary removal; Reconstruction (left): Saline implant; Reconstruction (right): Saline implant

Page 1 of 1 (1 results)